Brevan Howard Capital Management’s Summit Therapeutics SMMT Stock Holding History

Brevan Howard Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-11,351	Closed	-$235K	–	2242
2025 Q3	$235K	Sell	11,351 -93,309	-89%	-$2.26M	﹤0.01%	1683
2025 Q2	$2.23M	Buy	+104,660	New	+$2.39M	0.01%	692
2024 Q3	–	Sell	-31,214	Closed	-$243K	–	1414
2024 Q2	$243K	Buy	+31,214	New	+$169K	﹤0.01%	834

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PCMH

Polymer Capital Management (HK) Hong Kong $1.16B AUM 135.84% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Brevan Howard Capital Management's SMMT Position: Q4 2025 in Review

Brevan Howard Capital Management sold out of Summit Therapeutics (SMMT) in Q4 2025, closing a stake of 11,351 shares — an estimated $235K sold.

Brevan Howard Capital Management first reported a position in SMMT in Q2 2024 and held it in 3 quarters. The position peaked at $2.23M in Q2 2025. 206 funds tracked by Wall St. Rank hold SMMT as of Q4 2025.

Brevan Howard Capital Management reported no remaining Summit Therapeutics position as of Q4 2025 after selling out during the quarter.
Brevan Howard Capital Management sold 11,351 Summit Therapeutics shares in Q4 2025, an estimated $235K.
Brevan Howard Capital Management first reported a position in Summit Therapeutics in Q2 2024 and held it in 3 quarters.
Brevan Howard Capital Management's Summit Therapeutics position peaked at $2.23M in Q2 2025.
206 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2025.

Based on Brevan Howard Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.